Oral Lenalidomide and Intravesical BCG for Therapy of Bladder Cancer
Status:
Completed
Trial end date:
2018-12-10
Target enrollment:
Participant gender:
Summary
The purposes of this study are to:
- find out whether participants' cancer returns or gets worse while they are taking
lenalidomide and Bacille Calmette-Guerrin (BCG);
- evaluate the safety and tolerability of the combination of lenalidomide and BCG;
- compare the cancer progression of participants taking lenalidomide and BCG versus
participants taking only BCG
Phase:
Phase 2
Details
Lead Sponsor:
H. Lee Moffitt Cancer Center and Research Institute